Aptevo Therapeutics Inc. (APVO)
APVO Stock Price Chart
Explore Aptevo Therapeutics Inc. interactive price chart. Choose custom timeframes to analyze APVO price movements and trends.
APVO Company Profile
Discover essential business fundamentals and corporate details for Aptevo Therapeutics Inc. (APVO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
20 Jul 2016
Employees
37.00
CEO
Marvin L. White
Description
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
APVO Financial Timeline
Browse a chronological timeline of Aptevo Therapeutics Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 May 2026
Upcoming earnings on 12 Feb 2026
Upcoming earnings on 5 Nov 2025
Earnings released on 11 Aug 2025
EPS came in at -$8.40 surpassing the estimated -$83.20 by +89.90%.
Stock split effective on 27 May 2025
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 15 May 2025
EPS came in at -$87.80 falling short of the estimated -$84.20 by -4.28%.
Earnings released on 4 Mar 2025
EPS came in at -$82.37 falling short of the estimated -$7.75 by -962.84%.
Stock split effective on 4 Dec 2024
Shares were split 1 : 37 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 7 Nov 2024
EPS came in at -$17.39 surpassing the estimated -$20.65 by +15.79%.
Earnings released on 8 Aug 2024
EPS came in at -$60.51 surpassing the estimated -$69.93 by +13.47%.
Earnings released on 8 May 2024
EPS came in at -$360.51 surpassing the estimated -$510.87 by +29.43%.
Stock split effective on 6 Mar 2024
Shares were split 1 : 44 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 5 Mar 2024
EPS came in at -$6.16 surpassing the estimated -$18.04 by +65.85%, while revenue for the quarter reached $902.00K .
Earnings released on 14 Nov 2023
EPS came in at -$798.06 surpassing the estimated -$1.15K by +30.56%.
Earnings released on 10 Aug 2023
EPS came in at -$1.96K falling short of the estimated -$1.79K by -9.82%.
Earnings released on 11 May 2023
EPS came in at $414.99 surpassing the estimated -$1.90K by +121.85%.
Earnings released on 30 Mar 2023
EPS came in at -$0.95 surpassing the estimated -$1.53 by +37.91%, while revenue for the quarter reached -$3.11M .
Earnings released on 10 Nov 2022
EPS came in at -$2.44K surpassing the estimated -$2.62K by +6.71%.
Earnings released on 11 Aug 2022
EPS came in at -$2.97K falling short of the estimated -$2.12K by -39.85%.
Earnings released on 12 May 2022
EPS came in at -$2.54K falling short of the estimated -$1.84K by -38.26%, while revenue for the quarter reached $3.11M , missing expectations by -16.96%.
Earnings released on 24 Mar 2022
EPS came in at -$1.27 surpassing the estimated -$1.29 by +1.55%, while revenue for the quarter reached $3.67M , beating expectations by +7.79%.
Earnings released on 12 Nov 2021
EPS came in at -$2.31K surpassing the estimated -$2.36K by +2.03%, while revenue for the quarter reached $3.10M , missing expectations by -1.99%.
Earnings released on 12 Aug 2021
EPS came in at -$2.84K surpassing the estimated -$3.11K by +8.72%, while revenue for the quarter reached $3.11M , beating expectations by +245.56%.
Earnings released on 11 May 2021
EPS came in at -$2.78K falling short of the estimated -$2.59K by -7.41%, while revenue for the quarter reached $2.42M , missing expectations by -62.59%.
Earnings released on 31 Mar 2021
EPS came in at -$1.92 falling short of the estimated -$1.22 by -57.38%, while revenue for the quarter reached $2.37M .
Earnings released on 10 Nov 2020
EPS came in at -$3.43K falling short of the estimated -$3.27K by -4.88%, while revenue for the quarter reached $1.46M , beating expectations by +4.69%.
APVO Stock Performance
Access detailed APVO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.